Resources
65 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/5/2024 (updated 5/7/2024)
The U.S. Department of Health & Human Services released details of a plan for more than 200 actions across the federal government to address high rates of suicide.
Posted 10/25/2022 (updated 4/26/2024)
A guidebook from the Substance Abuse and Mental Health Services Administration describes various methods of adapting evidence-based practices for substance use disorder (SUD) to meet the needs of populations who experience barriers in receiving behavioral health services due to a variety of factors including race, ethnicity, geography, income, sexual orientation, and disability.
Posted 4/19/2024
April is Alcohol Awareness Month. This month offers a time to raise awareness and understanding of alcohol use and misuse. Resources and support is available for individuals struggling with alcohol use. In addition, the Substance Abuse and Mental Health Services Administration provides a social media toolkit for communities to utilize.
Posted 2/11/2022 (updated 4/11/2024)
This packet presents Implementation III grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 3/25/2021 (updated 4/5/2024)
State and Regional Focused Presentations: State Substance Use Prevention Systems and the National Prevention Network
Presenters will review the structure and function of state substance use prevention systems, describe the role and activities of the National Prevention Network, and highlight rural prevention initiatives.
Posted 2/10/2021 (updated 4/4/2024)
The Opioid Response Network is making available a new dental curriculum on SBIRT (screening, brief intervention and referral to treatment), an evidence-based approach to managing patients with or at risk of developing a substance use disorder (SUD).
The curriculum was developed for dentists by the ORN grant through a collaboration with the American Academy of Addiction Psychiatry and the Division on Substance Use Disorders, Columbia University Irving Medical Center/NYSPI.
Posted 3/28/2024 (updated 4/4/2024)
This presentation suggested RCORP grantees and the behavioral health system in general should scale up parenting classes provided to clients across the continuum.
Posted 11/9/2021 (updated 4/3/2024)
This workshop will explore the link between Adverse Childhood Experiences (ACEs) of individuals with substance use concerns and its impact on their development. We will explore the experiences, perceptions, beliefs, and behaviors that may present challenges in development. We will discuss practical, trauma-informed, outcome-driven strategies that improve the outcomes.